Logo image of TLT.CA

THERALASE TECHNOLOGIES INC (TLT.CA) Stock Fundamental Analysis

TSX-V:TLT - TSX Venture Exchange - CA88337V1004 - Common Stock - Currency: CAD

0.25  +0.01 (+2.04%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TLT. TLT was compared to 15 industry peers in the Health Care Equipment & Supplies industry. While TLT seems to be doing ok healthwise, there are quite some concerns on its profitability. TLT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLT had negative earnings in the past year.
TLT had a negative operating cash flow in the past year.
TLT had negative earnings in each of the past 5 years.
TLT had a negative operating cash flow in each of the past 5 years.
TLT.CA Yearly Net Income VS EBIT VS OCF VS FCFTLT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

TLT has a Return On Assets of -134.35%. This is in the lower half of the industry: TLT underperforms 73.33% of its industry peers.
TLT's Return On Equity of -202.38% is in line compared to the rest of the industry. TLT outperforms 53.33% of its industry peers.
Industry RankSector Rank
ROA -134.35%
ROE -202.38%
ROIC N/A
ROA(3y)-113.17%
ROA(5y)-88.66%
ROE(3y)-165.39%
ROE(5y)-122.16%
ROIC(3y)N/A
ROIC(5y)N/A
TLT.CA Yearly ROA, ROE, ROICTLT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

With a Gross Margin value of 51.71%, TLT perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
TLT's Gross Margin has been stable in the last couple of years.
TLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.85%
GM growth 5Y-0.79%
TLT.CA Yearly Profit, Operating, Gross MarginsTLT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLT has more shares outstanding
TLT has a worse debt/assets ratio than last year.
TLT.CA Yearly Shares OutstandingTLT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
TLT.CA Yearly Total Debt VS Total AssetsTLT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

TLT has an Altman-Z score of 2.83. This is not the best score and indicates that TLT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.83, TLT belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
TLT has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.10, TLT is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 2.83
ROIC/WACCN/A
WACC7.9%
TLT.CA Yearly LT Debt VS Equity VS FCFTLT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 1.91 indicates that TLT should not have too much problems paying its short term obligations.
TLT has a Current ratio of 1.91. This is in the better half of the industry: TLT outperforms 66.67% of its industry peers.
TLT has a Quick Ratio of 1.21. This is a normal value and indicates that TLT is financially healthy and should not expect problems in meeting its short term obligations.
TLT's Quick ratio of 1.21 is in line compared to the rest of the industry. TLT outperforms 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 1.21
TLT.CA Yearly Current Assets VS Current LiabilitesTLT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.74% over the past year.
The Revenue has decreased by -4.42% in the past year.
TLT shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.20% yearly.
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y4.83%
Revenue growth 5Y-9.2%
Sales Q2Q%23.66%

3.2 Future

TLT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.67% yearly.
Based on estimates for the next years, TLT will show a very strong growth in Revenue. The Revenue will grow by 221.79% on average per year.
EPS Next Y66.67%
EPS Next 2Y29.1%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue Next Year-24.75%
Revenue Next 2Y30.9%
Revenue Next 3Y221.79%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TLT.CA Yearly Revenue VS EstimatesTLT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
TLT.CA Yearly EPS VS EstimatesTLT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.02 -0.02 -0.04

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLT.CA Price Earnings VS Forward Price EarningsTLT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLT.CA Per share dataTLT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.01 -0 -0.01 -0.01

4.3 Compensation for Growth

TLT's earnings are expected to grow with 38.67% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.1%
EPS Next 3Y38.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERALASE TECHNOLOGIES INC

TSX-V:TLT (3/7/2025, 7:00:00 PM)

0.25

+0.01 (+2.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-27 2024-11-27/amc
Earnings (Next)03-25 2025-03-25/amc
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.59%
Ins Owner ChangeN/A
Market Cap61.95M
Analysts84.44
Price Target0.82 (228%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)46.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 62.78
P/FCF N/A
P/OCF N/A
P/B 28.96
P/tB 28.96
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -134.35%
ROE -202.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.71%
FCFM N/A
ROA(3y)-113.17%
ROA(5y)-88.66%
ROE(3y)-165.39%
ROE(5y)-122.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.85%
GM growth 5Y-0.79%
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.94%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 1.21
Altman-Z 2.83
F-Score4
WACC7.9%
ROIC/WACCN/A
Cap/Depr(3y)24%
Cap/Depr(5y)68.26%
Cap/Sales(3y)7.53%
Cap/Sales(5y)19.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y66.67%
EPS Next 2Y29.1%
EPS Next 3Y38.67%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y4.83%
Revenue growth 5Y-9.2%
Sales Q2Q%23.66%
Revenue Next Year-24.75%
Revenue Next 2Y30.9%
Revenue Next 3Y221.79%
Revenue Next 5YN/A
EBIT growth 1Y2.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.59%
OCF growth 3YN/A
OCF growth 5YN/A